Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + carboplatin + fosbretabulin + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Oncotelic Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of bevacizumab, carboplatin, fosbretabulin, and paclitaxel. Bevacizumab is an antibody that works by decreasing blood supply to tumors. Carboplatin is a platinum-containing compound that attacks fast-growing cancer cells. Paclitaxel is a chemotherapy agent that disrupts cell division. Fosbretabulin (combretastatin A4 phosphate) is a vascular disrupting agent. This combination may be used in the treatment of various cancers.
- Other names
- BCP plus fosbretabulin tromethamine
02
Targets
Beyond the preview
Go deeper on bevacizumab + carboplatin + fosbretabulin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + carboplatin + fosbretabulin + paclitaxel.